Abstract
This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.
Publication types
-
Observational Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Inhalation
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / adverse effects*
-
Adrenal Cortex Hormones / therapeutic use
-
Aged
-
Bronchodilator Agents / administration & dosage
-
Bronchodilator Agents / adverse effects*
-
Bronchodilator Agents / therapeutic use
-
Diabetes Mellitus, Type 2 / chemically induced*
-
Diabetes Mellitus, Type 2 / epidemiology
-
Female
-
Humans
-
Incidence
-
Male
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Risk Factors
-
Sweden / epidemiology
Substances
-
Adrenal Cortex Hormones
-
Bronchodilator Agents